HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome

Skenderi, Faruk; Alahmad, Mohamad Alhoda Mohamad; Tahirovic, Emin; Alahmad, Yaman M.; Gatalica, Zoran; Vranić, Semir

doi:10.1007/s10549-022-06578-4

Cited by 3 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SEER database includes demographic data, tumor characteristics (such as tumor type, histologic grade, TNM stage (AJCC), tumor size, lymph node status, and the presence or absence of distant metastases), treatment options (surgery, chemotherapy, radiotherapy), and follow-up for vital status. The SEER database encompasses clinicopathologic data from 18 population-based cancer registries, covering approximately one-third of the American population [10].…”

Section: Patients' Selection and Cohortsmentioning

confidence: 99%

See 1 more Smart Citation

Acinic Cell Carcinoma of The Breast: A Population-Based Clinicopathologic Study

Skenderi,

Babu,

Glamoclija

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose Acinic cell carcinoma (ACC) of the breast is a very rare, primary salivary gland-type breast malignancy with ~ 100 reported cases in the literature. Limited information about the clinical features and outcomes of the patients with ACC is available. Methods We utilized the Surveillance, Epidemiology, and End Results (SEER) database to identify ACC cases diagnosed between 2000 and 2018. For comparison, we also examined a cohort of invasive breast carcinomas of no special type (NST). Results Thirty ACC cases were identified among over 248,000 invasive breast carcinoma NST cases in the SEER database. Most ACC cases affected the White population (87%) and individuals over 50 years old (70%). ACCs were predominantly grade 3 carcinomas (44%), diagnosed at an early stage (AJCC TNM stages I and II, 67%). Hormone receptor (HR) and HER2 status were available for 13 cases, revealing molecular heterogeneity: HR-/HER2- (four cases, 31%), HR-/HER2+ (two cases, 15%), HR+/HER2- (four cases, 31%), and HR+/HER2+ (three cases, 23%). Surgery was the primary treatment modality for 26 out of 30 (86.7%) ACC patients, with chemotherapy and radiotherapy used in 46.7% and 33% of cases, respectively. The median survival time for ACC patients was 19 months compared to 48 months for invasive breast carcinoma NST patients (p < 0.001). Year-wise survival rates for ACC patients showed a dramatic decrease in the number of at-risk patients over time, starting at 30 months and decreasing rapidly, compared to a slower decline in the invasive breast carcinoma NST group (p < 0.01). The log odds of death for ACC patients were significantly higher (by 4.5 times) than for invasive breast carcinoma NST patients (p < 0.01), indicating a substantially worse prognosis. Conclusions Acinic cell carcinoma of the breast is a very rare (0.01%) primary breast malignancy. Despite its early clinical presentation, ACC of the breast appears to have a more aggressive clinical course and poorer clinical outcomes compared with conventional breast cancer.

show abstract

Section: Patients' Selection and Cohortsmentioning

confidence: 99%

“…In contrast, HER2 results were based on IHC and/or in situ hybridization tests. Based on the reported immunohistochemical expressions of ER and PR (hormonal receptors, [HR]), and HER2, all cases were classi ed into four molecular subtypes: HR+/HER2-, HR+/HER2+, HR-/HER2+, and HR-/HER2- [10].…”

Section: Patients' Selection and Cohortsmentioning

confidence: 99%

Acinic Cell Carcinoma of The Breast: A Population-Based Clinicopathologic Study

Skenderi,

Babu,

Glamoclija

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Apocrine lesions of breast and invasive carcinoma with apocrine differentiation: a brief review

Anjum,

Mooghal,

Rehman

et al. 2023

Surg Exp Pathol

View full text Add to dashboard Cite

SummaryApocrine metaplastic change is a frequent change in breast pathology. Invasive carcinoma with apocrine differentiation of the breast has unconventional histology, immunohistochemical (IHC), and molecular profile. It has an Estrogen receptor (ER)/Progesterone receptor (PR) negative and an Androgen receptor (AR) positive profile. About 1/3 of cases can show Her2neu amplification through IHC or Fluorescence in situ hybridization (FISH). Lymphovascular invasion (LVI) and lymph node metastasis (LNM) are frequently observed and they often have poor pathological response to chemotherapy. Histologically and molecularly defined apocrine subtypes of breast cancer, although have considerable overlap, yet are different and discrete entities. The decision on using chemotherapy and targeted regimens in these lesions is still controversial which calls for more insight. This could be achieved by acquiring a standardized diagnostic practice, further research, and discussion.

show abstract

Rare Breast Cancers Review

Song,

Singh

2024

Healthcare

View full text Add to dashboard Cite

Background/Objectives: Breast cancer is one of the most common malignancies in women, with rare subtypes presenting unique clinical challenges. This review provides a comprehensive analysis of rare breast cancers, including both epithelial and non-epithelial subtypes, and explores their epidemiology, pathology, prognosis, and treatment approaches. Methods: A systematic review was conducted focusing on recent advancements in the treatment of rare breast cancer subtypes. Articles were selected based on criteria emphasizing studies from the past five years, with older foundational studies included where necessary. The analysis incorporated molecular profiling, clinical trials, and advancements in targeted and immunotherapies, where possible. Results: Rare epithelial subtypes, such as tubular, mucinous, and medullary carcinomas, demonstrate distinct clinical and pathological features, with generally favorable prognoses compared to invasive ductal carcinoma (IDC). Non-epithelial cancers, including sarcomas and primary breast lymphomas, require individualized treatment due to aggressive behavior and poor prognosis in certain cases. Recent advancements in targeted therapies (e.g., HER2 inhibitors, PI3K inhibitors, and PARP inhibitors) and immunotherapies (e.g., PD-1 inhibitors) have shown promise in improving outcomes for specific molecularly characterized subtypes. Conclusions: While the management of common breast cancers has become increasingly sophisticated, rare subtypes continue to pose challenges due to limited research and small patient populations. Advances in molecular profiling and next-generation sequencing are pivotal in identifying actionable mutations and expanding personalized treatment options. Future research should focus on clinical trials and collaborative efforts to refine treatment strategies and improve outcomes for these rare subtypes.

show abstract

HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome

Cited by 3 publications

References 26 publications

Acinic Cell Carcinoma of The Breast: A Population-Based Clinicopathologic Study

Acinic Cell Carcinoma of The Breast: A Population-Based Clinicopathologic Study

Apocrine lesions of breast and invasive carcinoma with apocrine differentiation: a brief review

Rare Breast Cancers Review

Contact Info

Product

Resources

About